Beyond Air’s (XAIR) “Buy” Rating Reiterated at D. Boral Capital

Beyond Air (NASDAQ:XAIR)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $11.00 price target on the stock. D. Boral Capital’s target price points to a potential upside of 464.10% from the stock’s previous close.

A number of other research firms have also commented on XAIR. Rodman & Renshaw started coverage on shares of Beyond Air in a report on Tuesday. They set a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Beyond Air in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Beyond Air has an average rating of “Moderate Buy” and an average price target of $11.00.

Beyond Air Trading Up 14.7%

Shares of XAIR stock opened at $1.95 on Wednesday. The firm has a market cap of $15.62 million, a P/E ratio of -0.26 and a beta of 0.34. The business has a 50-day moving average price of $1.15 and a two-hundred day moving average price of $2.07. The company has a quick ratio of 3.73, a current ratio of 4.24 and a debt-to-equity ratio of 0.77. Beyond Air has a 12-month low of $0.67 and a 12-month high of $10.40.

Beyond Air (NASDAQ:XAIR) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.15). The business had revenue of $1.82 million during the quarter, compared to the consensus estimate of $2.54 million. Beyond Air had a negative return on equity of 261.08% and a negative net margin of 632.51%. Equities analysts anticipate that Beyond Air will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Beyond Air

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of Beyond Air by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 838,319 shares of the company’s stock valued at $144,000 after purchasing an additional 12,598 shares during the period. Alyeska Investment Group L.P. purchased a new stake in Beyond Air during the third quarter valued at approximately $1,753,000. Wealth Effects LLC raised its stake in shares of Beyond Air by 42.5% in the second quarter. Wealth Effects LLC now owns 278,100 shares of the company’s stock valued at $48,000 after acquiring an additional 83,000 shares during the period. Osaic Holdings Inc. lifted its stake in Beyond Air by 26.4% in the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after purchasing an additional 34,000 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Beyond Air in the 3rd quarter valued at $48,000. 31.50% of the stock is owned by hedge funds and other institutional investors.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.